TARA-002 for Bladder Cancer: Promising, But Not So Fast
Protara's TARA-002 reports a 68% six-month response rate in bladder cancer — but small sample sizes, dropping 12-month results, and incomplete enrollment raise serious concerns.
/ 3 items
#TARA↓
Major Biotech Upgrades and Coverage Initiations: Regeneron, Erasca, Protara, Design Therapeutics, Oric
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.
Protara Therapeutics Shares Climb on Strong Phase 2 Trial Results for TARA-002
Protara Therapeutics stock jumped after positive Phase 2 interim results showed strong response rates for TARA-002 in non-muscle invasive bladder cancer patients.